Prescribe PAXLOVID^
A GUIDE TO PRESCRIBING COVID-19 ORAL ANTIVIRALS FOR PBS-ELIGIBLE PATIENTS
This flowchart has been developed based on the Product Information and PBS eligibility criteria. It has been provided as guidance to help you in prescribing COVID-19 oral antivirals.
YES
Is the patient taking other medication( including OTC medication and herbal products)?
NO
Check for potential interactions between PAXLOVID and the patient’ s concomitant medication
Interactions can be checked using the University of Liverpool COVID-19 Drug Interactions Checker † or PAXLOVID Product Information. 1, 4, 5
Can drug interactions between PAXLOVID and the patient’ s concomitant medication be managed?
NO
YES
Does the patient have severe renal and / or severe hepatic impairment?
Consider prescribing an alternative COVID-19 oral antiviral 3, 4
YES
NO
Document details / reasons of contraindications to PAXLOVID in the patient’ s medical records 3
Prescribe PAXLOVID^
Dose adjustment is recommended for patients with moderate renal impairment( eGFR ≥30 to < 60 mL / min / 1.73m 2). 1 Scan the QR code for PAXLOVID dosage guidance.
^If clinically appropriate
†
Liverpool COVID-19 Drug Interactions Checker disclaimers:
1. Pfi zer was not involved in the development of the Liverpool Drug Interactions Checker, and the information contained in the Liverpool Drug Interactions Checker is neither owned nor controlled by Pfi zer. 2. Pfi zer accepts no responsibility for the content or services of the Liverpool Drug Interactions Checker, and excludes all warranties, express or implied, in connection with the use of the Liverpool Drug Interactions Checker, as well as all liability( including for negligence) for any personal injury or death, or loss, expense or damage( including loss of opportunity) whether direct, indirect, special or consequential, arising in any way out of or in connection with the use of the Liverpool Drug Interactions Checker. 3. Advice contained within the Liverpool Drug Interactions Checker may not be fully consistent with the Product Information of drugs registered in Australia, and Pfi zer makes no representations and gives no warranties as to the accuracy or currency of the information contained in the Liverpool Drug Interactions Tracker. 4. If a drug is not listed in the Liverpool Drug Interactions Checker, it should not be assumed it is safe for co-administration. 5. Refer to the Product Information( PI) of each medication taken by a patient prior to prescribing and dispensing an antiviral therapy, as well as the PI of the antiviral to be prescribed.
Abbreviations: AE: adverse event; eGFR: estimated glomerular fi ltration rate; OTC: over-the-counter; PBS: Pharmaceutical Benefi ts Scheme.
References: 1. PAXLOVID ® Product Information. 2. Pharmaceutical Benefi ts Scheme. Nirmatrelvir & Ritonavir. Available at: https:// www. pbs. gov. au / medicine / item / 12996B-13147Y. Accessed March 2024. 3. Pharmaceutical Benefi ts Scheme. Lagevrio ®( molnupiravir) Factsheet – Updated December 2024. Available at: https:// www. pbs. gov. au / publication / factsheets / covid-19-treatments / PBS-Factsheet-lagevrio-molnupiravir-updated-December-2024. pdf. Accessed January 2025. 4. Pharmaceutical Benefi ts Scheme. PAXLOVID ®( nirmatrelvir and ritonavir) Factsheet- Updated December 2024. Available at: https:// www. pbs. gov. au / publication / factsheets / covid-19-treatments / PBS-Factsheet-paxlovid-nirmatrelvir-and-ritonavir-updated-December-2024. pdf. Accessed January 2025. 5. COVID-19 Drug Interactions. University of Liverpool, 2024. Available at: https:// www. covid19-druginteractions. org / checker. Accessed January 2025. 6. Hammond J et al. N Eng J Med. 2022; 386:1397 – 1408.
© 2025. All rights reserved. Pfi zer Australia Pty Ltd, Sydney, Australia. www. pfi zer. com. au. Medical Information: 1800 675 229. www. pfi zermedicalinformation. com. au. PP-C1D-AUS-0435. AWF-2634470. 02 / 25.